Mohseni Afshar Zeinab, Ebrahimpour Soheil, Javanian Mostafa, Vasigala VeneelaKrishna Rekha, Masrour-Roudsari Jila, Babazadeh Arefeh
Clinical Research Development Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.
Caspian J Intern Med. 2020 May;11(3):244-249. doi: 10.22088/cjim.11.3.244.
In December 2019, a new virus called coronavirus disease 2019 (COVID-19) causing severe acute respiratory syndrome emerged in Wuhan, China, and rapidly spread to other areas of China and other regions of the world. Since it was a discovery, COVID-19 has spread to several countries and to this date, affecting about 2,329,651 people and caused about 160,721 deaths. Since most COVID-19 infected cases were diagnosed with pneumonia and characteristic chest computed tomography (CT) scan patterns, radiological examinations have become an important tool in early diagnosis. Nowadays, CT findings combined with normal blood cells (WBCs), lymphopenia and a history of epidemiological exposure have been used as criteria for clinical diagnosis of COVID-19. It is noteworthy that reverse transcription polymerase chain reaction (RT-PCR) test is still gold standard for the diagnosis. This review focuses on role of chest CT in the clinical evaluation of disease progression and more accurate diagnosis.
2019年12月，一种名为2019冠状病毒病（COVID-19）的新型病毒在中国武汉出现，引发严重急性呼吸综合征，并迅速传播至中国其他地区及世界其他地区。自发现以来，COVID-19已传播至多个国家，截至目前，已感染约2329651人，造成约160721人死亡。由于大多数COVID-19感染病例被诊断为肺炎且具有特征性的胸部计算机断层扫描（CT）模式，放射学检查已成为早期诊断的重要工具。如今，CT表现结合正常血细胞（白细胞）、淋巴细胞减少以及流行病学暴露史已被用作COVID-19临床诊断的标准。值得注意的是，逆转录聚合酶链反应（RT-PCR）检测仍是诊断的金标准。本综述重点关注胸部CT在疾病进展临床评估和更准确诊断中的作用。
